Characterization of Human γδ T Lymphocytes Infiltrating Primary Malignant Melanomas

Questionable Relevance of    T Lymphocytes in Renal Cell Carcinoma

(2014) B. A. Inman et al.   JOURNAL OF IMMUNOLOGY

Differentiation, phenotype, and function of interleukin-17-producing human V 9V 2 T cells

(2011) N. Caccamo et al.   BLOOD

The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis

(2011) M J M Gooden et al.   BRITISH JOURNAL OF CANCER

Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why?

(2011) Arcadi Cipponi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

High Phosphoantigen Levels in Bisphosphonate-Treated Human Breast Tumors Promote V 9V 2 T-Cell Chemotaxis and Cytotoxicity In Vivo

(2011) I. Benzaid et al.   CANCER RESEARCH

IL-21 enhances the potential of human γδ T cells to provide B-cell help

(2011) Raj R. Bansal et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Variation of tumor-infiltrating lymphocytes in human cancers: controversy on clinical significance

(2011) Tetsuro Sasada et al.   Immunotherapy

Identification of a Novel Proinflammatory Human Skin-Homing V 9V 2 T Cell Subset with a Potential Role in Psoriasis

(2011) U. Laggner et al.   JOURNAL OF IMMUNOLOGY

Presence of Tumor-Infiltrating Lymphocytes and a Dominant Nodule Within Primary Melanoma Are Prognostic Factors for Relapse-Free Survival of Patients With Thick (T4) Primary Melanoma

(2010) Uma N. M. Rao et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

(2010) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Partial and Ineffective Activation of V 9V 2 T Cells by Mycobacterium tuberculosis-Infected Dendritic Cells

(2010) S. Meraviglia et al.   JOURNAL OF IMMUNOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune reactions in benign and malignant melanocytic lesions: lessons for immunotherapy

(2010) R. Speeckaert et al.   Pigment Cell & Melanoma Research

γδ T Cells and the Lymphoid Stress-Surveillance Response

(2009) Adrian C. Hayday   IMMUNITY

Final Version of 2009 AJCC Melanoma Staging and Classification

(2009) Charles M. Balch et al.   JOURNAL OF CLINICAL ONCOLOGY

Reduced Expression of the Mevalonate Pathway Enzyme Farnesyl Pyrophosphate Synthase Unveils Recognition of Tumor Cells by V 9V 2 T Cells

(2009) J. Li et al.   JOURNAL OF IMMUNOLOGY

Spontaneous regression of metastases from melanoma: review of the literature

(2009) Louise Vennegaard Kalialis et al.   MELANOMA RESEARCH

A Rapid Crosstalk of Human γδ T Cells and Monocytes Drives the Acute Inflammation in Bacterial Infections

(2009) Matthias Eberl et al.   PLoS Pathogens

Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma

(2008) Jaafar Bennouna et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies

(2008) R. Berger et al.   CLINICAL CANCER RESEARCH

Dysregulation of the host mevalonate pathway during early bacterial infection activates human TCR γδ cells

(2008) Magdalena Kistowska et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens

(2008) Mark E. Dudley et al.   JOURNAL OF CLINICAL ONCOLOGY

Overcoming Immunologic Tolerance to Melanoma: Targeting CTLA-4 with Ipilimumab (MDX-010)

(2008) J. Weber   ONCOLOGIST

Overcoming Immunologic Tolerance to Melanoma: Targeting CTLA-4 with Tremelimumab (CP-675,206)

(2008) A. Ribas   ONCOLOGIST